A publicly traded biotechnology company might have just made a significant breakthrough in treating advanced breast cancer.
What’s happening:
- Clincal stage cancer biotechnology company BriaCell Therapeutics (NASDAQ: BCTX) has announced new positive data from their Phase II clinical trial for patients with advanced breast cancer
- The new data illuminates that a subset of patients who have advanced breast cancer got significant benefit from BriaCell’s Bria-IMT treatment despite previously failing to respond to Antibody-Drug Conjugates
Why it matters:
- Antibody-Drug Conjugates are one of the more significant recent advancements in cancer treatments but many patients either don’t respond favourably or experience serious side effects
- Finding new ways to effectively treat patients with advanced breast cancer remains one of the largest challenges needing to be solved for in cancer therapy as a whole
Going deeper:
- The new clinical data suggests BriaCell’s novel immunotherapy Bria-IMT could potentially be a breakthrough for treating patients with advanced breast cancer
By the numbers:
- Of 23 patients with advanced breast cancer in BriaCell’s clinical trial who had not responded to Antibody-Drug Conjugates, 17 of them are still alive presently after BriaCell’s Bria-IMT treatment
- 0 of the patients in the clinical trial reported any cases of Interstitial Lung Disease, which is an extremely common side effect of Antibody-Drug Conjugates
- There was a 40% disease control rate in patients in the clinical trial, which is more compelling validation of the clinical benefit of Bria-IMT
